or IFN-y (13, 14) . Partially purified MDF (pMDF) was prepared by using Sephadex G-100 chromatography. Active fractions on myeloma cell growth, whose apparent mol wt was 26,000, were used as pMDF.
ProliferativeAssays . Myeloma cells were washed and resuspended in RPM I 1640 with 8% FCS and 100 gg/ml piperacillin . A quantity of 104 cells was plated in 96-well flat-bottomed microplates and stimulated with MDF, various cytokines, or M(bs . For the inhibition assay using a-IL-6 antibody, MDF or recombinant cytokines were preincubated with a-IL-6 antibody (10 Itg/ml) for 1 h at 37°C and then myeloma cells were added to the culture . The culture was incubated for 96 h and pulsed for a final 24 h with 0.5 gCi [''H]thymidine .
['H]Thymidine incorporation was determined by scintillation counting.
Characterization of Myeloma Cell Lines. The methods for morphological analysis and cell surface marker analysis are described elsewhere (14) .
Results
Establishment and Characterization of Cell Lines . For the first 3 mo of the long-term cultures, myeloma cells proliferated very slowly on bone marrow-derived M(Ds and/or fibroblasts . 3 mo later, these cells could be transferred to the wells that were feeder layered with allogeneic MIN . They could also be maintained in the medium containing MDF and then in the medium containing 2 ng/ml rIL-6. Both cell lines, named ILKM2 and ILKM3, had the typical morphological features of myeloma cells as shown in Fig . 1 . The surface phenotype of both cells was PCA-1 + , OKT10 + , CD10-, CD19-, CD20-, CD21 -, and OKIa-1 -, showing a typical myeloma cell phenotype. Cytoplasmic Ig staining showed that IgG-K was positive in ILKM2 and only K chain was positive in ILKM3 . EBV nuclear antigen (EBNA) was negative in both cell lines . The population doubling time was 120 h for ILKM2 and 96 h for ILKM3, when they were cultured in the medium containing 2 ng/ml rIL-6.
Proliferation of ILKM2 or ILKM3. ILKM2 and ILKM3 did not proliferate spontaneously. They proliferated vigorously in the presence of allogeneic MOs (Fig. 2 , A and D) . MDF could substitute for the MO functions and induced the growth of myeloma cell lines in a dose-dependent manner (Fig. 2, B and E) . Among the cytokines examined, IL-6 had the strongest activity on the DNA synthesis in both cell lines (Fig . 3) . rIL-6, even at the dose of 0.05 ng/ml, had significant growth-enhancing 
activity (Fig. 2, C and F)
. IL-1a, IL-1ß, IFN-a and, to a lesser extent, TNFa also had growth-enhancing activity on ILKM2, however, these active factors were not competent for the maintenance of ILKM2. ILKM3 proliferated only in response to IL-6 or MDF (Fig. 3) . These results suggested that the myeloma cell growth activity in MDF was derived from IL-6 for the most part.
Inhibition ofMyeloma Cell Growth by a-IL-6 Antibody. a-IL-6 antibody completely inhibited rIL-6-dependent growth of ILKM2 and ILKM3 (Table I) . It also completely inhibited MDFdependent growth of ILKM2. Anti-IL-6 antibody only partially inhibited MDFinduced proliferation of ILKM3, but almost completely inhibited FIGURE 3. Proliferative responses of ILKM2 (A) and ILKM3 (B) to various recombinant cytokines. A quantity of 10 4 myeloma cells was cultured with various cytokines and the DNA synthesis was measured as described in Materials and Methods. The concentrations of cytokines used in these experiments were as follows: IL-1a, 2-20 ng/ml (20) ; IL-lß, 2-20 ng/ml (20) ; IL-2, 0.25-2.5 ng/ml (2 .5); IL-3, 1-10 U/ml (10); IL-4, 2-20 U/ml (20) ; IL-6, 0.4-4 ng/ml (4); IFN-a, 100-1,000 U/ml (100); IFN-p, 100-1,000 U/ml (100); IFN-y, 100-1,000 U/ml (100); G-CSF, 0.25-2.5 ng/ml (2 .5); GM-CSF, 0.25-2.5 ng/ml (2 .5); EGF, 10-100 ng/ml (100); and MDF, 5-50% (50) .
[3H]Thymidine uptake shows the maximum response in thosedose ranges . The dose of each cytokine described in parentheses was used in the experiments shown in Fig. 3 . (*) Native, fibroblast-derived IFN-ß was used in this experiment. Induced by rIL-6 MDF, or pMDF Anti-IL-6 antibody (10 4g/ml) or normal rabbit IgG (control IgG, 10 erg/ml) was preincubated with MDF, pMDF, or rIL-6 at 37°C for 1 h and the DNA synthesis in ILKM2 or ILKM3 was measured as described in Materials and Methods . MDF, macrophage culture supernatant ; pMDF, partially purified MDF (active fractions on myeloma cell growth, 26 kD), separated by Sephadex G-100 chromatography .
pMDFinduced proliferation of ILKM3 . These results indicated that IL-6 is the primary myeloma cell growth factor included in the MDF.
Discussion
In this report, we demonstrated that two bone marrow-derived myeloma cell lines proliferate dependently on MO feeder layers, MDF or rIL-6, and that both cell lines have been maintained in vitro in the medium containing rIL-6 for >1 yr.
Although autocrine mechanisms of myeloma cell growth have been documented by several authors (16, 17) , the establishment of spontaneously proliferating myeloma cell lines in vitro is extremely difficult (1) . In addition to autocrine mechanisms, paracrine mechanisms have also been suggested to play an important role in myeloma cell growth (1, 4, 18, 19) . Our results agree with the paracrine mechanisms of myeloma cell growth ; bone marrow-derived myeloma cell lines proliferate in the presence of MOs, MDF is able to substitute for the M(b functions, Mos produce IL-6, myeloma cell lines most strongly proliferate in response to rIL-6, a-IL-6 antibody inhibits the rIL-6-or MDFinduced proliferation of myeloma cell lines, and myeloma cell lines have been maintained for >1 yr in the medium containing rIL-6. Furthermore, two other bone marrow-derived myeloma cell lines have now been maintained for >6 mo by using MO feeder layers (unpublished observation) . This indicates that our method is reproducibly applicable for establishing myeloma cell lines. All this evidence, as well as the fact that MO is a constituent of bone marrow stromal cells, suggests that M(bs, through secreting IL-6, play a key role in the growth of myeloma cells in vivo. In accordance with our results, Nordan and Potter (19) demonstrated that murine plasmacytoma had developed exclusively from the mineral oil-induced granulomatous tissue composed of M(bs and neutrophils and the M(Dderived factor, which is now known to be identical to IL-6, was able to maintain mouse plasmacytoma cells in vitro. Since it was reported that IL-6 is an autocrine growth factor for human muliple myeloma (16) , both autocrine and paracrine mechanims, mediated through IL-6, may be involved in the in vivo growth of myeloma cells.
The proliferative response of ILKM2 to IL-la, IL-lß, and IFN-a is also interesting. Another myeloma cell line (KMI) and several fresh myeloma cells also proliferate in response to IL-1 (unpublished observation) . Furthermore, in addition to IL-6, ILKM3 appears to proliferate in response to a monokine or monokines that are different from the known monokines examined (Fig . 3 and Table I ) . IL-1 and TNF a are known to induce IL-6 secretion from fibroblasts (7-9). Although we could not detect IL-6 activity in the culture supernatant of both cell lines when they were cultured with various mitogens or cytokines, a possibility that IL-6 produced by myeloma cells binds to their own IL-6-Rs immediately after secretion is not excluded . Whether IL-1, IFN-a, or other unknown factors induce IL-6 secretion from myeloma cells, and whether another myeloma cell growth factor exists or not, remains to be elucidated in the future .
Our data imply that MOs or IL-6 can be uesd to establish bone marrow-derived myeloma cell lines more efficiently and that myeloma cells established could be used for the analysis of myeloma cell growth regulation by cytokines or drugs. These studies may open up a new approach to the treatment of MM .
Summary Two IL-6-dependent human multiple myeloma cell lines, ILKM2 and ILKM3, were established from the bone marrow of patients with IgG-K multiple myeloma. Both cell lines had the typical morphology and immunocytochemical features of myeloma cells. The surface phenotype of both cell lines was PCA-1 + , OKT10+, CD10(J-5) -, CD19(B4) -, CD20(Bl) -, CD21(B2) -, and OKIa-1 -. A monoclonal cytoplasmic Ig, IgG-K or K L chain, was positive in ILKM2 or ILKM3, respectively. EBV nuclear antigen was negative in both cell lines. They proliferated in the presence of macrophages or macrophage-derived factors (MDF). Among the recombinant cytokines examined, IL-6 most strongly augmented the growth of both cell lines. The anti-IL-6 antibody completely inhibited the IL-6-dependent growth and almost completely inhibited the MDF or purified MDF-dependent growth of both cell lines. ILKM2 and ILKM3 are now being maintained in the culture medium containing 2 ng/ml rIL-6.
These results suggest that IL-6 produced by macrophages may play an important role in the growth of myeloma cells in vivo and that macrophages or IL-6 can be used for establishing human myeloma cell lines.
Receivedfor publication 5 July 1988 and in revised form 23 September 1988.
